Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

It was a busy week in the biotech sector with earnings reports from bigwigs Biogen BIIB and Bristol Myers Squibb BMY. Other ...

Incyte (NASDAQ:INCY) has agreed to acquire Escient Pharmaceuticals, a privately held biotech focused on developing small-molecule drugs for immune and neuro-immune disorders, the companies ...

Incyte's stock has declined by 31% in the past year due to concerns about the 2029 patent expiration for Jakafi, its high-margin drug. Investors are seeking assets that can generate revenue before ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

It was a busy week in the biotech sector with earnings reports from bigwigs Biogen and Bristol Myers Squibb. Other regulatory ...

Monday closed up +0.32%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.38%, and the Nasdaq 100 Index ($IUXX) ...